Daejeon, South Korea

Joo-Young Im

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 11.0

ph-index = 1


Company Filing History:


Years Active: 2021

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Joo-Young Im: Innovator in Cancer Treatment

Introduction

Joo-Young Im is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of pharmaceutical compositions for cancer treatment. His innovative work focuses on utilizing the CYB5R3 gene or protein as an active ingredient in cancer therapies.

Latest Patents

Joo-Young Im holds a patent for a pharmaceutical composition aimed at preventing and treating cancer. This composition contains cytochrome b5 reductase 3 (CYB5R3) protein as its active ingredient. The invention highlights that the over-expression of CYB5R3 in cancer cells leads to a significant reduction in hypoxia-inducible factor-1α (HIF-1α) expression. This reduction results in the inhibition of cancer cell growth both in vitro and in vivo. Therefore, the CYB5R3 gene or protein can be a valuable component in pharmaceutical compositions for cancer treatment.

Career Highlights

Joo-Young Im is affiliated with the Korea Research Institute of Bioscience and Biotechnology. His work at this esteemed institution has allowed him to focus on groundbreaking research in cancer treatment and biotechnology. His dedication to innovation has positioned him as a key figure in the scientific community.

Collaborations

Joo-Young Im collaborates with notable colleagues, including Mi Sun Won and Hyun Seung Ban. These partnerships enhance the research and development efforts in the field of cancer treatment.

Conclusion

Joo-Young Im's contributions to cancer treatment through his innovative patent demonstrate the potential of biotechnology in addressing critical health challenges. His work continues to inspire advancements in the medical field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…